Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis

Weijia Li(Jacobi Medical Center), Damianos G. Kokkinidis(Memorial Hospital of South Bend), Stefanos Giannopoulos(Denver VA Medical Center), Dimitrios Kalaitzoglou(National and Kapodistrian University of Athens), Yu-Chiang Wang(Jacobi Medical Center), Apostolos Manolopoulos(National Institute on Aging), Leonidas Palaiodimos(Albert Einstein College of Medicine), Paraschos Archontakis‐Barakakis(Albert Einstein College of Medicine), Robert Faillace(Jacobi Medical Center), Lazaros Tzelves(National and Kapodistrian University of Athens)
World Journal of Cardiology
April 21, 2021
Cited by 7


Related Papers